Amyotrophic lateral sclerosis (ALS) is an uncommon neurodegenerative disease caused by degeneration of upper and lower motor neurons. Several genes, including SOD1, TDP-43, FUS, Ubiquilin 2, C9orf72 and Profilin 1, have been linked with the sporadic and familiar forms of ALS. FUS is a DNA/RNA-binding protein (RBP) that forms cytoplasmic inclusions in ALS and frontotemporal lobular degeneration (FTLD) patients' brains and spinal cords. However, it is unknown whether the RNA-binding ability of FUS is required for causing ALS pathogenesis. Here, we exploited a Drosophila model of ALS and neuronal cell lines to elucidate the role of the RNA-binding ability of FUS in regulating FUS-mediated toxicity, cytoplasmic mislocalization and incorporation into stress granules (SGs). To determine the role of the RNA-binding ability of FUS in ALS, we mutated FUS RNA-binding sites (F305L, F341L, F359L, F368L ) and generated RNA-binding-incompetent FUS mutants with and without ALS-causing mutations (R518K or R521C). We found that mutating the aforementioned four phenylalanine (F) amino acids to leucines (L) (4F-L) eliminates FUS RNA binding. We observed that these RNA-binding mutations block neurodegenerative phenotypes seen in the fly brains, eyes and motor neurons compared with the expression of RNA-binding-competent FUS carrying ALS-causing mutations. Interestingly, RNA-binding-deficient FUS strongly localized to the nucleus of Drosophila motor neurons and mammalian neuronal cells, whereas FUS carrying ALS-linked mutations was distributed to the nucleus and cytoplasm. Importantly, we determined that incorporation of mutant FUS into the SG compartment is dependent on the RNA-binding ability of FUS. In summary, we demonstrate that the RNA-binding ability of FUS is essential for the neurodegenerative phenotype in vivo of mutant FUS (either through direct contact with RNA or through interactions with other RBPs).
INTRODUCTION
Identification of mutations in FUS and TDP-43, both RNAbinding proteins (RBPs), in familial and sporadic forms of amyotrophic lateral sclerosis (ALS) and frontotemporal lobular degeneration (FTLD) patients suggested that disruption in RNA metabolism might be a key event in ALS pathogenesis (1 -6) . FUS and TDP-43 are ubiquitously expressed, multifunctional proteins involved in regulating several functional aspects of RNA metabolism, such as transcription, pre-mRNA splicing and microRNA processing through RNA/ DNA and protein -protein interactions (1, 2, (7) (8) (9) (10) (11) (12) . Interestingly, both of these ALS-causing proteins reside predominantly in the nucleus and possess similar structural organization (1, 2, 13, 14) . Cytoplasmic mislocalization of FUS in ALS and FTLD patients' neurons has been frequently observed and has been predicted to be a causative factor of neurodegeneration, suggesting that mutant FUS acquires a toxic gain-of-function in the cytoplasm (1, 2) .
The RNA-binding ability of FUS and TDP-43 has been suggested to be relevant to ALS pathogenesis because the physical interaction between these two proteins is RNA-dependent, and treatment with RNase blocks interaction of TDP-43 and FUS in a mammalian cell culture model system (15, 16) . A recent study in Caenorhabditis elegans demonstrated that mutating amino acid residues that mediate the RNA-binding ability of TDP-43 were sufficient to block TDP-43-mediated toxicity in the worms, suggesting that the RNA-binding ability of TDP-43 is important for ALS pathogenesis (17) . Furthermore, it has been recently shown that treatment with RNase decreased complex formation between TDP-43 and Drosha in a dose-dependent manner (18) . Molecular mechanisms of the RNA-binding ability of TDP-43 in regulating toxicity are not yet known.
Recent approaches combining RNA cross-linking, immunoprecipitation and high-throughput sequencing (PARCLIP/ iCLIP/CLIP-seq) led to the discovery of RNA targets of FUS and TDP-43 and indicated that both proteins are involved in pre-mRNA splicing, as FUS-bound RNA target sequences were found to be preferentially localized in long intronic regions and near-splice-site acceptors (19, 20) . It has been demonstrated that post-transcriptional regulatory cascades controlled by RBPs (such as FUS and TDP-43) and microRNAs play critical roles in mRNA maturation and gene regulation (20 -23) . FUS shuttles into the cytoplasm, particularly in neurons, suggesting that FUS is also involved in regulating both mRNA transport into neurites and local protein synthesis at synapses, two processes that are essential to neurons for a rapid response to stimuli (13) . Furthermore, it has been recently shown that FUS and TDP-43 incorporate into stress granules (SGs) under cellular stress conditions that negatively control mRNA translation, thus supporting the notion that FUS in the cytoplasmic compartment is in association with translation machinery (24) (25) (26) . SGs are cytoplasmic aggregates that contain polyadenylated mRNAs, translation initiation factors, small ribosome subunits and RBPs (24, 27) . Induction of SG formation under cellular stress conditions is believed to serve as a transient protective mechanism by shifting energy expenditure toward cellular repair and recovery while blocking de novo translation. Incorporation of FUS and TDP-43 into the cytoplasmic SGs under oxidative stress conditions suggests that motor neurons of ALS patients may have a defect in their ability to recover from stress conditions which might be related to motor neuron degeneration in ALS patients. Despite tremendous progress in the ALS research field, the role of the RNA-binding ability of FUS in causing FUS-related neurodegeneration is not yet clear.
In the present study, we examined the contribution of the RNA-binding ability of FUS in causing neurodegenerative phenotypes in a Drosophila model of FUS-related proteinopathies. We mutated four conserved phenylalanines to leucines (amino acids 305, 341, 359 and 368 of human FUS) in the RNA recognition motif (RRM) domain (referred to as 4F-L herewith) and observed that, although both wildtype and mutant FUS without 4F-L mutation do bind RNA, the 4F-L mutations are sufficient to abolish RNA binding in both FUS 4F-L, FUS 4F-L R518K and FUS 4F-L R521C. We found that mutating these RNA-binding residues (4F-L) of FUS blocks its ability to cause neurodegenerative phenotypes in vivo. Furthermore, RNA-binding-incompetent FUS carrying ALS-causing mutations predominantly localizes to the nucleus in both a neuronal cell line and Drosophila motor neurons, suggesting that cytoplasmic localization of mutant FUS is dependent on its RNA-binding ability. We also observed that RNA-binding-incompetent FUS does not localize in the SGs under stress conditions. Altogether, these findings suggest that the RNA-binding ability of FUS is essential for causing ALS pathogenesis. Furthermore, identification of mechanisms regulating RNA and protein targets of FUS that result in toxicity when FUS carries ALS mutations will help in developing therapeutic interventions for this devastating disease.
RESULTS

RNA-binding-incompetent FUS does not bind RNA and becomes non-toxic in vivo
In order to determine whether mutating four conserved phenylalanines to leucines (4F-L) of FUS perturbs its RNA-binding ability, we immunoprecipitated HA-FUS UV-crosslinked to RNA in neuronal (N2a) cell lines stably expressing human FUS WT, FUS R518K, FUS 4F-L or FUS 4F-L R518K. Subsequent to radiolabeling-bound RNA, we found an RNA smear on an autoradiogram, indicating RNA binding by FUS was observed in the FUS WT and FUS R518K cells, but observed almost no RNA smear in the FUS 4F-L and FUS 4F-L R518K samples as well as none in non-transfected cells and in the pull-down with a non-specific antibody (Fig. 1A) . The autoradiograph was then probed with an anti-HA antibody which showed that HA-FUS protein was pulled down in all expected lanes, demonstrating that FUS 4F-L protein levels are still maintained despite the elimination of bound RNA. Western blots of whole-cell lysates of input samples showed that HA-FUS protein is present in all samples except for the nontransfected cells (Fig. 1A, bottom panel) .
To further determine the consequences of disrupting RNA binding of FUS carrying ALS-causing mutations, we expressed FUS 4F-L and FUS 4F-L R518K in yeast cells. We found that FUS 4F-L (single mutant) and FUS 4F-L R518K (double mutant) did not cause any significant toxicity when compared with FUS WT and FUS R518K expression, which did cause increased cell death in the yeast cells when expressed at equal levels ( Fig. 1B and C) . These findings are consistent with a previous study where ectopic expression of FUS 4F-L itself did not cause any toxicity in yeast cells (28) .
We recently developed a Drosophila model of FUS-related proteinopathies that recapitulates several key features of ALS, such as mutation-dependent toxicity, neurodegeneration and cytoplasmic mislocalization (29) . In order to investigate the role of the RNA-binding ability of FUS on toxicity, we generated Drosophila lines expressing the UAS-FUS 4F-L, UAS-FUS 4F-L R518K and UAS-FUS 4F-L R521C constructs. We targeted the expression of RNA-binding-incompetent mutants to the fly eyes, using the GMR-gal4 driver. Interestingly, we observed that the expression of RNA-bindingincompetent FUS (4F-L) with or without ALS-causing mutations did not lead to any significant external eye degeneration when compared with FUS WT, FUS R518K and FUS R521C ( Fig. 1C and D) . We performed quantification of eye phenotypes, using previously published criteria, and found a significant difference in the external eye degenerative phenotypes of flies expressing RNA-binding-incompetent FUS when compared with mutant FUS-expressing animals (Fig. 1D) . Interestingly, mutating RNA-binding residues did not alter FUS protein levels and we observed equal levels of FUS in RNA-binding-incompetent lines when compared with both WT and mutant FUS-expressing lines (Fig. 1F) . We also investigated whether deletion of the RRM (DRRM) domain had an effect similar to the 4F-L mutants. We generated transgenic lines expressing FUS DRRM, FUS DRRM R518K and FUS DRRM R521C. We targeted the expression of these FUS DRRM constructs to the Drosophila eyes, using the GMR-gal4 driver. We observed that deletion of the RRM domain of FUS strongly blocks toxicity associated with ALS-causing mutations in FUS (Supplementary Material, Fig. S1 ).
Neuronal expression of mutant FUS with 4F-L mutations (RNA-binding-incompetent) alleviates the behavioral abnormalities as well as smaller brain size caused by mutant FUS alone
Previously, we showed that motor neuron expression of mutant FUS caused eclosion defects and larval paralysis in a fly model of FUS-related ALS (29) . Because ALS is a motor neuron disease, we asked whether the RNA-binding ability of FUS is required for causing an eclosion defect in animals expressing FUS under the control of the neuronal driver Elav-gal4. We found that RNA-binding-incompetent FUSexpressing lines (FUS 4F-L) eclose significantly better when compared with FUS R518K and FUS R521C. The FUS 4F-L lines demonstrated eclosion rate similar to FUS-WTexpressing animals ( Fig. 2A) . In order to determine whether the expression of RNA-binding-incompetent FUS causes any larval locomotor dysfunction, we performed larval crawling assays (29) (30) (31) . As expected, mutant FUS-expressing animals (UAS-FUS R518K) showed severe larval paralysis when compared with FUS WT or driver-alone controls (Fig. 2B) . Interestingly, animals expressing RNA-binding-incompetent FUS (4F-L) with or without ALS-linked mutations in the motor neurons did not cause larval paralysis when compared with FUS WT or a driver-alone control, suggesting that the RNA-binding ability of FUS is important for causing larval paralysis in Drosophila (Fig. 2B) . Importantly, we observed that mutating RNA-binding residues (4F-L) significantly blocked toxicity associated with FUS WT, and larvae expressing FUS 4F-L were able to crawl better when compared with FUS WT-expressing animals ( Fig. 2B) .
Normally, Drosophila larvae crawl in a forward direction by peristaltic movement accompanied by rhythmic and coordinated waves (32) . These movements require muscle contractions passing along the body-wall segments in a posterior-to-anterior direction. To investigate consequences of the expression of FUS WT and FUS carrying ALS-causing mutations on larval body-wall contraction, we targeted the expression of transgenes to the motor neurons and performed body-wall-contraction assays. We observed a severe defect in body-wall contractions of animals expressing FUS R518K and FUS R521C when compared with FUS WT and driveralone control (Fig. 2C) . Interestingly, consistent with larval crawling assay, we found that animals expressing FUS 4F-L showed better body-wall contraction when compared with FUS WT animals, suggesting that the 4F-L mutation can significantly reduce toxicity associated with FUS WT (Fig. 2C) .
To further delineate the effects of FUS expression on motor coordination, we performed larval righting assays that measure anterior -posterior and dorsal ventral motor coordination (33) . Third instar larvae were turned ventral side up and the time taken for them to roll back to their dorsal side was recorded (righting assay). We found that motor neuron expression of FUS R518K and FUS R521C severely compromised their ability to right themselves (Fig. 2D) . However, RNAbinding-incompetent FUS (4F-L) with or without ALScausing mutations in FUS showed better turning when compared with FUS WT (Fig. 2D ). Of note, we also observed that animals expressing FUS 4F-L were able to turn better when compared with FUS WT animals, indicating that RNA-binding-incompetent FUS alone can reduce toxicity associated with FUS WT (Fig. 2D) .
Altogether, these behavioral assays strongly suggest that the RNA-binding ability of FUS is important for causing toxicity and that mutating the RNA-binding residues of FUS is enough to abolish this toxicity.
Next, we asked whether the behavioral defects in Drosophila larvae associated with mutant FUS can be explained by defects in gross brain morphology. We observed that the expression of mutant FUS in motor neurons (OK371-gal4 driver) caused smaller brain size due to brain atrophy in third instar larvae, suggesting that the expression of mutant FUS, but not RNA-binding-incompetent FUS, causes a defect in gross brain morphology in Drosophila larvae (Fig. 3) . These observations are consistent with a recent study showing that the expression of a neurodegenerative disease-causing protein leads to smaller larval brains similar to the mutant FUS-expressing animals (34) . It is possible that the mutant FUS expression might cause developmental defect followed by atrophy or vice versa in the early stages of development. Further investigation using conditional expression system would help in addressing the possibility if small brain sizes are due to developmental defects or atrophy.
RNA-binding-incompetent FUS predominantly localizes to the nucleus of mammalian neuronal cells
FUS predominantly resides in the nucleus in normal cells and shuttles between the nucleus and cytoplasm (1, 2, 35) . Abnormal cytoplasmic mislocalization of mutant FUS has been shown in human ALS patients' neurons as well as in several animal models (1, 2, 36) . We reasoned that if the RNA-binding ability of FUS is involved in the cytoplasmic localization of mutant FUS, we would expect predominantly nuclear localization of RNA-binding-incompetent FUS. We stably expressed FUS WT, FUS R518K, FUS 4F-L and FUS 4F-L R518K (all HA-tagged) in the neuroblastoma N2a cell line. We found that the stably transfected neuronal cells have equal FUS expression as expected (Supplementary Material, Fig. S2 ). Next, we immunostained the stably transfected cells with anti-HA (green) and DRAQ5 (blue; nuclear staining) and examined them by confocal microscopy. As expected and previously reported, FUS WT predominantly localized in the nucleus, whereas FUS R518K was observed in both the cytoplasm and nucleus (Fig. 4A) . Surprisingly, we observed predominant localization of both RNA-binding-incompetent FUS with or without ALS-causing mutations in the nucleus (Fig. 4A) . We performed quantification of nuclear and cytoplasmic distribution of FUS and found significant differences in the distribution pattern of RNA-binding-incompetent FUS when compared with FUS R518K (Fig. 4B) . These observations suggest that cytoplasmic mislocalization of mutant FUS is mediated via the RNA-binding ability of FUS and mutating RNA-binding residues restricts FUS protein to the nucleus. However, we did not find obvious toxicity in the N2a cells transiently transfected with either FUS WT or FUS R518K in the XTT assay performed under serum starvation conditions as well as in normal serum (Supplementary Material, Fig. S3 ).
RNA-binding-incompetent FUS predominantly localizes to the nucleus of Drosophila motor neurons
To investigate subcellular distribution of FUS in fly motor neurons, we targeted the expression of UAS FUS WT, UAS FUS R518K, UAS FUS R521C and UAS FUS 4F-L R521C to the motor neurons, using the OK371-gal4 driver. We immunostained the cells for Lamin as a nuclear marker to highlight the nuclear envelope membrane, and thus staining inside the Lamin ring is nuclear and outside the ring is cytoplasmic (29) . As expected, WT FUS predominantly localized in the nucleus, whereas UAS-FUS R518K and FUS R521C were distributed in the cytoplasm and nucleus as demonstrated by the immunofluorescence of FUS (green) and Lamin (red) (Fig. 5) . WT FUS can be clearly seen localized to the nucleus, whereas mutant FUS R518K and FUS R521C staining ( Fig. 5C and E, arrows) is seen in the nucleus and also in the cytoplasm, outside of the Lamin ring (Fig. 5A) . Interestingly, we found that RNA-binding-incompetent FUS (UAS FUS 4F-L, UAS FUS 4F-L R518K and UAS FUS 4F-L R521C) predominantly localized in the nucleus, suggesting that cytoplasmic mislocalization of mutant FUS is dependent on the RNA-binding ability of FUS, and cytoplasmic localization of mutant FUS is important for causing ALS pathogenesis. 
RNA-binding-incompetent FUS does not incorporate into the cytoplasmic SGs
It has been previously demonstrated that FUS carrying ALScausing mutations incorporates into the cytoplasmic SGs under stress conditions and is important for ALS pathogenesis (24) . We asked whether this incorporation of mutant FUS is dependent on the RNA-binding ability of FUS. To address this issue, we stressed neuronal N2a cell lines stably expressing FUS WT, FUS R518K, FUS 4F-L and FUS 4F-L R518K (all HA-tagged), with sodium arsenite for 1 h as described previously (24) . We immunostained the cells with anti-HA (green, FUS), anti-TIAR (red, SG marker) and DRAQ5 (blue, nuclear marker) and examined them by confocal microscopy. We observed that FUS R518K, but not WT FUS, incorporates into the cytoplasmic SGs under stressed condition (Fig. 6) . Importantly, RNA-bindingincompetent FUS (FUS 4F-L and FUS 4F-L R518K) did not incorporate into the cytoplasmic SGs under stress conditions. We performed analogues experiment under unstressed condition and we did not find any evidence of colocalization of FUS with SGs (Supplementary Material, Fig. S4 ). We performed quantification of cells showing localization of FUS in the cytoplasmic SGs and found a significant difference in the incorporation of FUS R518K and RNA-bindingincompetent FUS R518K into the cytoplasmic SGs (Supplementary Material, Fig. S5 ).
DISCUSSION
FUS and TDP-43 are two key RBPs implicated in ALS and several other neurodegenerative diseases (1 -3)
. Recent studies demonstrated that FUS and TDP-43 interact with a large number of RNA targets, suggesting that these proteins' interactions with RNA may have important roles in pathways involved in neurodegenerative diseases (19, 20) . Interestingly, disease-causing mutations in FUS do not disrupt the RNAbinding ability of FUS, suggesting the possibility that mutant FUS might interact with a different set of mRNAs or with the same set of RNAs with different affinity when compared with WT FUS (1). Massive numbers of RNAs bind to both WT and mutant forms of FUS, suggesting that FUS is part of a large RNA -protein network and thus a slight disruption in this network due to disease-associated mutations might be enough to cause the motor neuron degeneration observed in ALS (19, 20) . We found that mutating conserved phenylalanine residues to leucine (4F-L) in the RRM of FUS impairs the RNAbinding abilities of both FUS 4F-L and FUS 4F-L R518K, suggesting that these residues are critical for mediating RNAprotein interactions without destabilizing FUS protein expression. Previously, it has been shown that the expression of FUS 4F-L does not cause any obvious toxicity in yeast cells (28) . We observed that the ectopic expression of FUS 4F-L with ALS-causing mutations (R518K or R521C) does not cause toxicity in yeast cells (Fig. 1A) , suggesting that RNAbinding-incompetent FUS with ALS-causing mutations becomes non-toxic in yeast cells similar to FUS 4F-L. We also investigated whether the RNA-binding-incompetent FUS with or without ALS-causing mutations becomes nontoxic in a whole animal model system. To address this, we utilized a Drosophila model of FUS-related proteinopathies that recapitulates several key features of ALS, such as mutation-dependent toxicity and locomotor dysfunctions when expressed in the fly eyes and motor neurons, respectively. We found that targeted expression of RNA-bindingincompetent FUS in the Drosophila eyes does not lead to any significant external eye degeneration, suggesting that the RNA-binding ability of FUS is important for causing neurodegeneration in vivo.
We next asked whether mutating the RNA-binding ability of FUS can also block locomotor dysfunctions associated with motor neuron expression of mutant FUS. Previously, we demonstrated that motor neuron expression of mutant FUS leads to an eclosion rate defect and larval paralysis in Drosophila (29) . We observed that the RNA-bindingincompetent FUS with or without ALS-causing mutations did not cause an eclosion rate defect or larval paralysis when compared with FUS WT-, FUS R518K-or FUS R521C-expressing animals. Moreover, mutating the RNAbinding ability of FUS also strongly suppressed decreased body-wall contractions and larval turning phenotypes associated with the expression of FUS carrying ALS-causing mutations. These results further support our hypothesis that disrupting the RNA-binding property of FUS is enough to make FUS carrying ALS mutations non-toxic. Because cytoplasmic mislocalization of FUS carrying an ALS-causing mutation is a pathological hallmark of ALS in human patients as well as in several animal models, we wished to determine the subcellular distribution of RNA-binding-incompetent FUS in a mammalian neuronal cell culture model system. We observed that similar to WT FUS, RNA-binding-incompetent FUS with or without ALScausing mutations predominantly resides in the nucleus, suggesting that cytoplasmic mislocalization of FUS associated with disease-causing mutations is dependent on the RNAbinding ability of FUS. We further investigated this question in flies expressing RNA-binding-incompetent FUS in the motor neurons. We found that RNA-binding-incompetent FUS predominantly localizes in the nucleus, further supporting our hypothesis that cytoplasmic localization of mutant FUS is mediated through the RNA-binding ability of FUS. It is possible that regulation of subcellular distribution of FUS by its RNA-binding ability might be important to ALS pathogenesis and that cytoplasmic mislocalization of mutant FUS might be mediated by RNA binding. Along this line, the FUS protein could form an FUS -RNA complex before being transported to the cytoplasm, and mutating 4F-L residues might disrupt this complex formation, which in turn leads to predominant nuclear localization of RNA-binding-incompetent FUS. Alternatively, FUS carrying ALS-causing mutations might be transported to the cytoplasm via other RBPs, and, along these lines, the 4F-L mutations could disrupt a complex of FUS with other RBPs, thereby blocking transport to the cytoplasm. Additionally, mutant FUS might be involved in cytoplasmic sequestering of protein or RNAs critical for maintaining nuclear functions, and this non-specific transport could lead to motor neuron degenerative pathologies observed in ALS patients.
Cytoplasmic SGs are transient structures that arise upon exposure to cellular stress such as infection, heat, oxidative insult and hypoxia. SGs are considered as a protective response against adverse cellular conditions, storing mRNAs important for maintaining cellular homeostasis. The SG, which is a nonmembranous structure, sequesters mRNAs encoding for housekeeping proteins responsible for triage, degradation and translational re-initiation (37) . On the one hand, SGs selectively down-regulate the translation of housekeeping mRNAs to conserve energy to cope with the stress-mediated damage, and on the other hand, SGs up-regulate synthesis of proteins such as DNA-repair proteins, chaperone proteins and various transcriptional factors. In addition to mRNAs, SGs also contain several RBPs, such as TDP-43, FUS, poly(A)-binding protein 1 and T-cell intracellular antigen 1. Previous studies have demonstrated that marker proteins that label SGs colocalize with the pathological FUS inclusions in postmortem brains of ALS and FTLD (26, 38) .
Molecular mechanisms underlying incorporation of FUS with ALS-associated mutations into SGs still remain an enigma. We observed that RNA-binding-incompetent FUS with ALS-causing mutations does not colocalize with SGs in the neuronal cells under stress conditions, suggesting that incorporation of mutant FUS into SGs is RNA-dependent. It is possible that transportation of mutant FUS is either directly or indirectly regulated by the RNA-binding ability of FUS or through other RBPs and that mutating the RNA-binding residues of FUS might impair the ability of FUS to localize into SGs under cellular stress conditions. A recent study supports our observations that the RNA-binding abilities of FUS and TDP-43 play important roles in SG formation (26) . Moreover, the study from Bentmann et al. (39) also suggests that FUS domains that do not bind artificial RNA (UG-rich RNA) in in vitro assays also contribute to SG assembly. The experiments performed by Bentmann et al. (39) rely on the deletion of different functional domains of FUS which might disrupt the three-dimensional architecture of FUS protein when compared with our study, where we mutated the conserved phenylalanine residues to leucines (4F-L); hence, it is difficult to conclude that non-RNA-binding domains of FUS also contribute to SG formation. Moreover, it is possible that differences between our study and Bentmann et al. (39) are due to the use of different cell lines for performing the assays.
Our data demonstrate the role of the RNA-binding ability of FUS in ALS pathogenesis and support the notion that incorporation of mutant FUS into the cytoplasmic SGs is important for FUS-mediated ALS pathogenesis. Our study cannot rule out the possibility of any structural changes in the FUS protein due to mutations in the RNA-binding residues. However, further investigations would help in determining whether 4F-L mutation also causes structural changes in the FUS protein structure, which in turn blocks the toxicity. On the basis of our results, we expect that the RNA-binding ability of mutant FUS would be a logical target for a potential drug for treating ALS patients.
MATERIALS AND METHODS
Antibodies, plasmids and cell culture
The human FUS cDNA plasmid (pDONR-FUS-RRM-4F-L) containing four phenylalanine-to-leucine mutations (amino acids 305, 341, 359 and 368 of human FUS) in the RRM domain of FUS was a generous gift of Dr Aaron Gitler (28) . Analogous mutation of four phenylalanines to leucines in the closely related TDP-43 protein has been shown to abolish RNA binding (40) . The 713 bp fragment spanning the 4F-L mutations was isolated following double digestion with restriction enzymes Bsu36I and PpuI (New England Biolabs, MA, USA) and inserted into similarly prepared pUAST-based vectors (Drosophila expression vectors pUAST-FUS-WT, pUAST-FUS-R518K and pUAST-FUS-R521C). Subcloning was done using standard methods, and isolated clones were verified as correct by analytical restriction digests and DNA sequencing. These pUAST constructs (pUAST FUS 4F-L, pUAST FUS 4F-L R518K and pUAST FUS 4F-L R521C) were sent to BestGene (Chino Hills, CA, USA) to generate transgenic flies.
To transfer each of the three FUS constructs into the pCIneo eukaryotic expression vector, the pUAST plasmids were digested with XhoI and XbaI. The isolated fragments were subcloned into the similarly prepared pCIneo vectors to generate pCIneo FUS 4F-L and pCIneo FUS-4F-L R518K. Isolated clones were verified by analytical restriction digests. The aforementioned two 4F-L clones and also pCIneo FUS-WT and pCIneo FUS-R518K were then transfected into the mouse neuro-N2a cell line, using TurboFect (Fermentas, MD, USA), following the manufacturer's suggested protocol. Positive clones were selected and maintained by including 500 mg G418/ml in the culture medium. The medium was advanced DMEM supplemented to contain 10% FBS and 1× GlutaMax (all from Life Technologies, Grand Island, NY, USA).
XTT assay to measure cell toxicity
To measure differences in cell proliferation of Neuro2a cells, a standard curve was constructed to determine the number of cells within the range of detection for the assay. Standards were performed in triplicate. For the assay, 50 000 cells were seeded in triplicate in a 96-well tissue culture plate and were allowed 24 h to adhere. Fresh DMEM media containing 5% FBS was added and assayed using ATCC XTT Cell Proliferation Assay Kit (Cat. # 30-1011k) for 3 h using the manufacturer's instructions. Data from three trials containing three replicates of each sample were compiled.
To measure cell viability by XTT assay, cells were serumstarved in DMEM media without FBS and treated with aphidicolin (400 ng/ml, Calbiochem) for 48 h. Two independent trials containing triplicates of each sample were averaged together. Data were analyzed using ANOVA with post hoc analysis using Tukey's at an alpha level of 0.05.
RNA-binding assay
The protocol used was adapted from the HITS-CLIP protocol used in Chi et al., 2009 (http://ago.rockefeller.edu/Ago_ HITS_CLIP_Protocol_June_2009.pdf). Briefly, the cells were suspended in PXL lysis buffer and homogenized followed by the addition of a 1:2500 dilution of RNase I (Ambion, AM2295) and a 1:250 dilution of Turbo DNase. The samples were then incubated for 3 min at 378C and then transferred to ice. The cell lysate was spun at 48C at 22 500g for 30 min and the supernatant was carefully collected. The supernatant was incubated with Protein G Dynabeads that had been pre-bound with monoclonal anti-HA antibody HA-7, and then rotated for 4 h at 48C. On the beads, the protein-bound RNA was treated with calf intestinal alkaline phosphate and then ligated with a radiolabeled 3 ′ RNA linker. After stringent washing, the samples were run on a NuPage 4 -12% Bis -Tris gel and transferred to a nitrocellulose membrane for autoradiography exposure to detect the bound RNA and subsequently probed with anti-HA to detect protein levels, using the Li-COR Odyssey system.
Yeast expression and immunoblotting
FUS-GFP fusion proteins were expressed in Saccharomyces cerevisiae strain W303 as previously described (41) . Yeast cells were grown at 308C in standard synthetic media containing either 2% glucose or 2% galactose (for the induction of protein expression). FUS proteins were expressed using the GAL1 promoter from plasmids derived from pFPS298 (CEN, URA3). The plasmids are designated as follows: pDK346 (FUS-GFP), pDK400 (FUS 4F-L-GFP), pDK405 (FUS R518K-GFP), pDK518K 406 (FUS 4F-L R518K-GFP). The high-copy plasmid DK248 (2m, URA3, FUS-GFP) was used as an additional control during immunoblotting.
Protein expression levels were confirmed by western blotting, using cultures grown for 6 h in 2% galactose, harvested and washed once with water. Cell pellets were re-suspended in lysis buffer [50 mM Tris -HCl, pH 7.5, 200 mM NaCl, 3 mM EDTA, 5% glycerol, 5 mM DTT and Complete protease inhibitor mixture (Roche, Indianapolis, IN, USA)]. Cells were physically disrupted by vigorous agitation with acid-washed glass beads for 3 min at 48C. Cellular debris was removed by low-speed centrifugation (10 min at 1500g). BCA reagent (Pierce, Rockford, IL, USA) was used to normalize protein concentrations. Yeast lysates were subjected to SDS/PAGE (Any kD gels, Bio-Rad) and transferred to PVDF membranes (Bio-Rad). Immunoblotting was performed according to standard protocols. The following antibodies were used: mouse monoclonal a-GFP (Roche), mouse monoclonal a-PGK1 and secondary AP-conjugated a-mouse (Invitrogen).
Drosophila culture, light microscopy and quantification
The FUS WT, FUS R518K and FUS R521C transgenic flies and GMR-gal4 and OK371-gal4 drivers were described previously (29) . Eye phenotypes of 1-day-old flies were analyzed with a Leica M205C stereomicroscope and photographed with a Leica DFC420 digital camera. For each genotype and condition, more than 25 flies were evaluated and quantification of eye phenotypes was done as described previously (29) .
Larval brain size determination
All isolated fly brains were isolated and photographed with a dissecting scope (Leica M205C), using the same distance and magnification. All images were analyzed using NIH ImageJ under identical conditions. A line was drawn around the perimeter of each brain. The relative area was determined. For each brain, this was done in triplicate, and the average was used as the relative area of the brain. This was done for multiple brains of each genotype. This cumulative data were then analyzed.
Drosophila behavioral assays
Eclosion assays Eclosion assays were carried out using the methodology published previously (29) .
Crawling assay
We performed the larval crawling assay, using a previously published method (29, 30) . Before starting the assays, vials containing larvae were kept at room temperature for 20 min. After removing third instar larvae from food vials, they were washed in PBS to remove any residual food and were allowed to crawl on a 1% agar plate for 1 min as described previously (29) .
Righting assay
For the righting assay, third instar wandering larvae were placed on agar plates and allowed to acclimatize for 5 min at room temperature. The larvae were then placed ventral side up and the time taken to return back to a crawling position/dorsal side upward was recorded. Twenty to 25 larvae were used per genotype and time taken was recorded in seconds.
Contraction assay
For the contraction assay, larvae were placed on agar plates and allowed to acclimatize for 5 min. The number of full-body peristaltic contractions in 30 s was recorded (31) . Note that FUS R521C larvae lost all their ability to right themselves. Interestingly, RNA-binding-incompetent FUS-expressing animals demonstrated normal larval turning ability similar to FUS WT and driver-alone controls. The asterisks represent significant difference between groups * P , 0.05, * * P , 0.001, * * * P , 0.0001 and NS (not significant).
Statistical analysis
For all behavioral assays, data were analyzed using one-way ANOVA. Tukey's post hoc analysis was then applied with multiple comparisons between each group under an alpha level of 0.05. Differences were considered statistically significant when P , 0.05; however, we do report when P , 0.001 and P , 0.0001.
Immunohistochemistry
Subcellular localization
Wandering third instar larvae were dissected and fixed in 4% formaldehyde for 15-25 min. Antibodies used included anti-FUS (Bethyl Labs, cat. # A300 -302A, 1:1000), anti-Lamin DmO (ADL67.10, at 1:100, developed by Paul Fisher and obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the Department of Biology, University of Iowa, Iowa City, IA, USA). For secondary staining, anti-rabbit Alexa Fluor 488 (Invitrogen, cat. # A-11008, 1:500) and antimouse Alexa Fluor 546 (Invitrogen, cat. # A-11003, 1:500) were used. After staining, larval cuticles with intact CNS were mounted in ProLong Gold (Invitrogen, cat. # P36930). Images were captured with a Leica SP2-TCS confocal microscope. All motor neurons imaged were located in the dorsal midline of the ventral ganglion.
Stable Neuro2a cell lines were taken off of G418 selection for 5 days prior to assay. In total, 100 000 cells were allowed to adhere to cover slips pre-coated with 0.01% poly-L-lysine (Sigma, cat. #P4832). The medium was changed to contain DRAQ5 [Abcam, cat. # ab108410 (5 mM For the subcellular localization analysis, only cells positive for FUS were considered. For the quantification of subcellular localization, cytoplasmic staining was counted as present when pixel intensity was at least 10 times the background fluorescence. Pixel intensity was determined using ImageJ (http://rsbweb.nih.gov/ij/).
SG induction
Stable Neuro2a cell lines were taken off of G418 selection for 5 days prior to the assay. In total, 100 000 cells were allowed to adhere to cover slips coated with 0.01% poly-L-lysine (Sigma, cat. #P4832). The medium was changed to contain 0.5 mM sodium arsenite (Ricca Chemical Co., cat # 7142-16) as described previously (24) . For quantifying FUS incorporation into SGs, only cells which both stained positive for FUS and contained cytoplasmic SGs were considered in the analysis (60 cells). Cytoplasmic staining was counted as present when pixel intensity was at least 10 times the background fluorescence. Pixel intensity was determined using ImageJ (http://rsbweb.nih.gov/ij/). Incorporation of FUS into SGs was considered positive when FUS directly colocalized with the SG marker TIAR.
